---
schema_version: "secwatch.filing_event.v1"
accession: "0001267602-24-000029"
form_type: "8-K"
ticker: null
cik: "0001267602"
company_name: "ALIMERA SCIENCES INC"
filed_at: "2024-05-14T23:59:59+00:00"
generated_at: "2026-06-02T00:21:04.520988+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Alimera Q1 revenue up 70% to $23M; adjusted EBITDA positive; reaffirms FY guidance

## Summary
- Net revenue $23.0M (+70% YoY); US $14.6M (+92%), International $8.5M (+42%).
- Net loss $6.3M vs $5.0M loss in Q1 2023; adjusted EBITDA positive $1.8M vs ($2.4M) loss.
- Global end user demand 4,028 units (+23% YoY). Reaffirms FY2024 revenue of $105M and ≥20% EBITDA margin.
- Completed enrollment in Synchronicity Study (YUTIQ for uveitis); first patient randomized in DRCR Retina Network study for radiation retinopathy.
- NICE recommends ILUVIEN for phakic DME patients in UK; increased term loan by $5M with SLR Capital.

## SEC filing metadata
- accession: 0001267602-24-000029
- form_type: 8-K
- cik: 0001267602
- company_name: ALIMERA SCIENCES INC
- filed_at: 2024-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1267602/000126760224000029/0001267602-24-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1267602/000126760224000029/alim-20240514x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001267602-24-000029
- JSON: https://secwatch.observer/filing/0001267602-24-000029.json
- Plain text: https://secwatch.observer/filing/0001267602-24-000029.txt

## Key facts
- Earnings Releases
  ALIMERA SCIENCES INC reported first quarter of 2024 results: revenue $23.0 million. Guidance reaffirmed.
  - Period: first quarter of 2024
  - Revenue: $23.0 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: such a filing. ‎ 2 --- EX-99.1 (EX-99.1) --- Exhibit 99.1     FOR IMMEDIATE RELEASE   Alimera Sciences Reports First Quarter 202 4 Results  · Net Revenue up 70 % to $ 23 Million vs. Q1 202 3 · Global End User Demand Up 2 3 % vs. Q1 202 3 · Re iterates I mproved 2024 Net Revenue and Adjusted EBITDA G uidance  ATLANTA , May 14 , 202 4 -- Alimera Sciences,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1267602/000126760224000029/0001267602-24-000029-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.